Aptevo and Alligator to co-develop bispecific antibody for tumor-directed immunotherapy

21 July 2017

Aptevo Therapeutics (Nasdaq: APVO) and Alligator Bioscience (Nasdaq Stockholm: ATORX), biotech companies based in the USA and Sweden respectively, have agreed to co-develop an immunotherapy bispecific antibody candidate, ALG.APV-527.

This candidate is based on Alligator’s first-generation bispecific antibody, ATOR-1016, and includes proprietary binding elements generated by the company’s antibody library. It was developed using Aptevo’s bispecific technology platform.

Working under a previously executed material transfer agreement, the companies have engineered and selected ALG.APV-527 as a lead bispecific antibody candidate, featuring a novel mechanism of action targeting 4-1BB, a member of the TNFR superfamily of co-stimulatory receptors found on activated T-cells, and an undisclosed tumor antigen widely overexpressed in a number of different types of cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK